Price movement over the last 24 hours
ADMA Biologics Inc vs Teucrium Wheat Fund — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Teucrium Wheat Fund trades at $22.77. The key difference: Teucrium Wheat Fund is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | WEAT | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $20.38 | $25.49 |
52-Week Low | $7.60 | $19.88 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
WEAT (Teucrium Wheat Fund) trades at $22.93, up 2.32% today, while technical indicators signal a bearish trend with moving averages showing sell pressure. The fund faces headwinds from reduced USDA wheat production forecasts and inflation concerns. Key support sits at $22 with resistance at $23, creating a tight trading range amid neutral oscillator readings.
Outlook remains cautious given agricultural commodity volatility and macroeconomic pressures. Investment opportunity exists for hedging against inflation, but risks include weather-dependent production and Federal Reserve policy impacts on commodity prices.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →